OmniSeq Advance

Roswell Park Comprehensive Cancer Center subsidiary OmniSeq and the Laboratory Corporation of America have launched a molecular cancer assay, OmniSeq Advance. The test involves next-generation sequencing and immunohistochemistry to assess specific genomic alterations, tumor mutational burden, microsatellite instability, the tumor microenvironment, and markers associated with immunotherapy. LabCorp will distribute the test.